Gefitinib 500mg Versus 250mg in Patients With NSCLC With Stable Disease After a Month Treatment of Gefitinib 250mg
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
This is a multi-center phase II randomized controlled study to assess the efficacy of
Gefitinib 500mg in patients with IIIB/IV staged non-small cell lung cancer(NSCLC) with stable
disease after a month treatment of 250mg Gefitinib by DCR,also PFS and OS.The side effect is
evaluated as well.